Oxypurinol

DB05262InvestigationalSmall molecule

Oxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol.

Mechanism: Oxypurinol inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid. Elevated concentrations of oxypurine and oxypurine inhibition of xanthine oxidase through negative feedback results in a decrease in the concentrations of uric acid in the blood and urine. Oxypurinol also facilitates the incorporation of hypoxanthine and xanthine into DNA and RNA, resulting in further reductions of serum uric acid concentrations.
Curator reviewed
Primary indication: Intended for the treatment of congestive heart failure and hyperuricemia.Curator reviewed
Formula / weight: C₅H₄N₄O₂ · 152.1109 g/mol (avg)
Also known as: Alloxanthine · DHPP · Oxipurinol · Oxoallopurinol
Code names: B. W. 55-5 · NSC-76239

Resolves to

Compound

Structure

InChIKeyHXNFUBHNUDHIGC-UHFFFAOYSA-NSMILESO=C1NC2=C(C=NN2)C(=O)N1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Oxypurinol, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.